<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792957</url>
  </required_header>
  <id_info>
    <org_study_id>DokuzEU-Rheumatology-1</org_study_id>
    <nct_id>NCT04792957</nct_id>
  </id_info>
  <brief_title>JAK-STAT Signaling Pathway in Pyoderma Gangrenosum</brief_title>
  <official_title>Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothese that Janus kinase/signal transduction and activator of&#xD;
      transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma&#xD;
      gangrenosum (PG). In this study JAK/STAT signaling pathway will be investigated in the skin&#xD;
      biopsies of PG patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytokines are key molecules in the pathogenesis of inflammatory diseases. These molecules&#xD;
      exert their effects through cell surface receptors and intracellular signaling pathways.&#xD;
      Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway&#xD;
      is implicated in the pathogenesis of several autoimmune diseases. Pyoderma gangrenosum (PG)&#xD;
      is an inflammatory skin disease characterized by progressive and recurrent skin ulceration of&#xD;
      destructive course. Treatment of PG requires aggressive immunosuppressive therapy but despite&#xD;
      the use of several agents, including tumor necrosis factor inhibitory treatments there is&#xD;
      still an unmet need in refractory PG. Recent reports suggested activation of JAK/STAT pathway&#xD;
      in PG and some case-based studies suggested the beneficial effect of JAK-STAT inhibitory&#xD;
      agent in the treatment of PG.&#xD;
&#xD;
      Skin biopsies obtained from PG, hidradenitis suppurativa, psoriasis and healthy subjects will&#xD;
      be studied to evaluate JAK/STAT pathway by using immunohistochemical methods. The following&#xD;
      immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1,&#xD;
      JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining&#xD;
      intensity will be recorded categorically (negative and positive). The positive staining will&#xD;
      also be graded semi-quantitively as follows: mildly positive, moderately positive and&#xD;
      strongly positive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of JAK-STAT pathway</measure>
    <time_frame>15 years</time_frame>
    <description>Expression of JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6 in tissue levels in PG.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pyoderma Gangrenosum</condition>
  <condition>Hidradenitis Suppurativa</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Pyoderma Gangrenosum</arm_group_label>
    <description>Skin biopsies obtained from patients with pyoderma gangrenosum will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hidradenitis Suppurativa</arm_group_label>
    <description>Skin biopsies obtained from patients with hidradenitis suppurativa, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <description>Skin biopsies obtained from patients with psoriasis, will be studied to evaluate JAK/STAT pathway by using immunohistochemical methods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <description>Skin biopsies obtained from patients with healthy subjects, will be used to control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>immunohistochemical methods</intervention_name>
    <description>The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Hidradenitis Suppurativa</arm_group_label>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_label>Pyoderma Gangrenosum</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from İzmir Katip Çelebi University, Ataturk Education and Research Hospital&#xD;
        Department of Rheumatology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pyoderma gangrenosum diagnosed with skin biopsy&#xD;
&#xD;
          -  Psoriasis diagnosed with skin biopsy&#xD;
&#xD;
          -  Hidradenitis suppurativa diagnosed with skin biopsy&#xD;
&#xD;
          -  Skin biopsy in healthy subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - This is a case-based study and there is no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ismail Sari, M.Sc</last_name>
    <phone>+902324122222</phone>
    <email>ismailsari35@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuba Demirci Yıldırım, M.D.</last_name>
    <phone>+902324122222</phone>
    <email>tubademirci87@gmail.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Ismail Sari</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>JAK-STAT pathway</keyword>
  <keyword>Pyoderma Gangrenosum</keyword>
  <keyword>Skin Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Pyoderma</mesh_term>
    <mesh_term>Pyoderma Gangrenosum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

